211 related articles for article (PubMed ID: 15150180)
1. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians.
Nix DE; Majumdar AK; DiNubile MJ
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii23-8. PubMed ID: 15150180
[TBL] [Abstract][Full Text] [Related]
2. Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy.
Goldstein EJ; Snydman DR
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii29-36. PubMed ID: 15150181
[TBL] [Abstract][Full Text] [Related]
3. Ertapenem: a Group 1 carbapenem with distinct antibacterial and pharmacological properties.
Hammond ML
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii7-9. PubMed ID: 15150178
[TBL] [Abstract][Full Text] [Related]
4. Treatment of complicated urinary tract infection in adults: combined analysis of two randomized, double-blind, multicentre trials comparing ertapenem and ceftriaxone followed by appropriate oral therapy.
Wells WG; Woods GL; Jiang Q; Gesser RM
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii67-74. PubMed ID: 15150185
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data.
Gesser RM; McCarroll K; Teppler H; Woods GL
J Antimicrob Chemother; 2003 May; 51(5):1253-60. PubMed ID: 12697633
[TBL] [Abstract][Full Text] [Related]
6. Ertapenem.
Parakh A; Krishnamurthy S; Bhattacharya M
Kathmandu Univ Med J (KUMJ); 2009; 7(28):454-60. PubMed ID: 20502094
[TBL] [Abstract][Full Text] [Related]
7. Ertapenem: a new opportunity for outpatient parenteral antimicrobial therapy.
Tice AD
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii83-6. PubMed ID: 15150187
[TBL] [Abstract][Full Text] [Related]
8. Ertapenem versus ceftriaxone for the treatment of community-acquired pneumonia in adults: combined analysis of two multicentre randomized, double-blind studies.
Ortiz-Ruiz G; Vetter N; Isaacs R; Carides A; Woods GL; Friedland I
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii59-66. PubMed ID: 15150184
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of ertapenem versus ceftriaxone in a double-blind study performed in children with complicated urinary tract infection, community-acquired pneumonia or skin and soft-tissue infection.
Arguedas A; Cespedes J; Botet FA; Blumer J; Yogev R; Gesser R; Wang J; West J; Snyder T; Wimmer W;
Int J Antimicrob Agents; 2009 Feb; 33(2):163-7. PubMed ID: 18945594
[TBL] [Abstract][Full Text] [Related]
10. Ertapenem (Invanz)--a new parenteral carbapenem.
Med Lett Drugs Ther; 2002 Mar; 44(1126):25-6. PubMed ID: 11941264
[No Abstract] [Full Text] [Related]
11. Safety and tolerability of ertapenem.
Teppler H; Gesser RM; Friedland IR; Woods GL; Meibohm A; Herman G; Mistry G; Isaacs R
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii75-81. PubMed ID: 15150186
[TBL] [Abstract][Full Text] [Related]
12. Properties and potential of ertapenem.
Livermore DM; Sefton AM; Scott GM
J Antimicrob Chemother; 2003 Sep; 52(3):331-44. PubMed ID: 12917243
[TBL] [Abstract][Full Text] [Related]
13. Ertapenem or ticarcillin/clavulanate for the treatment of intra-abdominal infections or acute pelvic infections in pediatric patients.
Yellin AE; Johnson J; Higareda I; Congeni BL; Arrieta AC; Fernsler D; West J; Gesser R
Am J Surg; 2007 Sep; 194(3):367-74. PubMed ID: 17693284
[TBL] [Abstract][Full Text] [Related]
14. Ertapenem.
Congeni BL
Expert Opin Pharmacother; 2010 Mar; 11(4):669-72. PubMed ID: 20163277
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis: ertapenem for complicated intra-abdominal infections.
Falagas ME; Peppas G; Makris GC; Karageorgopoulos DE; Matthaiou DK
Aliment Pharmacol Ther; 2008 May; 27(10):919-31. PubMed ID: 18266994
[TBL] [Abstract][Full Text] [Related]
16. Ertapenem for the treatment of extended-spectrum beta-lactamase-producing Gram-negative bacterial infections.
Teng CP; Chen HH; Chan J; Lye DC
Int J Antimicrob Agents; 2007 Oct; 30(4):356-9. PubMed ID: 17631986
[TBL] [Abstract][Full Text] [Related]
17. Ertapenem: a review of its use in the management of bacterial infections.
Curran M; Simpson D; Perry C
Drugs; 2003; 63(17):1855-78. PubMed ID: 12921489
[TBL] [Abstract][Full Text] [Related]
18. Treatment of complicated community-acquired infections with ertapenem, the first Group 1 carbapenem. Introduction.
Goldstein EJ
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii5-6. PubMed ID: 15228047
[No Abstract] [Full Text] [Related]
19. Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactam.
Solomkin J; Teppler H; Graham DR; Gesser RM; Meibohm AR; Roy S; Woods GL
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii51-7. PubMed ID: 15150183
[TBL] [Abstract][Full Text] [Related]
20. Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice.
Burkhardt O; Derendorf H; Welte T
Expert Opin Pharmacother; 2007 Feb; 8(2):237-56. PubMed ID: 17257093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]